{"id":"d2da7e25d0a4","type":"article","url":"https://hartvaat.nl/2017/01/01/ontwikkeling-van-linkerventrikelhypertrofie-bij-behandelde-hypertensie-campania-/","title":"Ontwikkeling van linkerventrikelhypertrofie bij behandelde hypertensie: Campania Salute Network","title_en":"Development of Left Ventricular Hypertrophy in Treated Hypertensive Outpatients: The Campania Salute Network.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","bloeddrukbehandeling","hartrevalidatie","renale-denervatie","summit-trial","vrouwen"],"journal":"Hypertension (Dallas, Tex. : 1979)","doi":"10.1161/HYPERTENSIONAHA.116.08158","source_url":"https://doi.org/10.1161/HYPERTENSIONAHA.116.08158","authors":["Raffaele Izzo","Maria-Angela Losi","Eugenio Stabile","Mai Tone Lönnebakken","Grazia Canciello","Giovanni Esposito","Emanuele Barbato","Nicola De Luca","Bruno Trimarco","Giovanni de Simone"],"significance":6,"published":"2017-01-01","source_date":"2017-01-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/wat-is-hypertensie/","https://hartvaat.nl/kennis/hypertensie/eindorgaanschade-hypertensie/"],"congress":"","summary_en":"This study documented the development of new left ventricular hypertrophy in treated hypertensive outpatients, showing that LVH can progress despite blood pressure therapy and identifying predictors of treatment failure.","created":"2026-07-03T10:26:30Z","updated":"2026-07-03T18:38:29Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie naar de ontwikkeling van linkerventrikelhypertrofie bij poliklinisch behandelde hypertensieve patiënten ondanks therapie. Identificeert risicofactoren voor progressieve orgaanschade.","abstract_original":"UNLABELLED: There is little information on left ventricular (LV) hypertrophy (LVH) development during antihypertensive treatment. We evaluate incident LVH in a treated hypertensive cohort, the Campania Salute Network registry. We analyzed prospectively 4290 hypertensives (aged 50.3±11.1 years, 40% women) with at least 1-year follow-up, without LVH at baseline. Incident LVH was defined as the first detection of echocardiographic LV mass index ≥47 in women or ≥50 g/m2.7 in men. During a median 48-month follow-up, 915 patients (21.3%) developed LVH. They were older, more frequently women, and obese (P<0.0001), with initial higher fasting glucose, diastolic and systolic blood pressure, LV mass index, lower heart rate and glomerular filtration rate, longer hypertension history and follow-up, and higher average systolic blood pressure during follow-up (all P<0.05), despite a more frequent treatment with Ca++-channel blockers and diuretics (both P<0.02). At multivariable Cox regression, incident LVH was independently associated with older age, female sex, obesity, higher average systolic blood pressure during follow-up, and initial greater LV mass index (all P<0.02). By categorizing patients according to obesity and sex, obesity independently increased the risk for incident LVH in both sexes (obese versus nonobese men: hazard ratio, 1.34; confidence interval, 1.05-1.72; P=0.019; and obese versus nonobese women: hazard ratio, 1.34; confidence interval, 1.08-1.66; P=0.007). Despite more aggressive antihypertensive therapy, 21% of hypertensive patients develop clear-cut LVH. After adjusting for confounders, risk of incident LVH is particular relevant among women and is further increased by the presence of obesity. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02211365."}